-
Dr Deng on the Effects of MSH6 on PARP Inhibitor Sensitivity in Ovarian Cancer
11 Jul 2025 03:27 GMT
… and PARylation-mediated signaling regulate PARP inhibitor resistance and sensitivity … PARP1 interactions between PARP inhibitor–sensitive and PARP inhibitor–resistant cell … in the sensitive cells, conferring PARP inhibitor resistance, Deng explained. …
-
Ovarian Cancer Drugs Market to Hit $7.2 Billion by 2035, Driven by Rising FDA Approvals and 2024's $4.2 Billion Base
14 Jul 2025 07:02 GMT
… technologies, and increasing use of PARP inhibitors and immunotherapy-based therapies … Drugs Market by Drug Class
• PARP Inhibitors
• Angiogenesis Inhibitors
• PD-L1 …
-
Nanoformulations Downregulating METTL16 Combined with mRNA Tumor Vaccines Suppress Triple-Negative Breast Cancer and Prevent Metastasis
11 Jul 2025 13:29 GMT
… , Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple …
-
HTMC0435 Plus Chemotherapy Yields Responses in Relapsed ES-SCLC
11 Jul 2025 13:12 GMT
Combining the oral PARP inhibitor HTMC0435 with temozolomide (Temodar) …
-
drugs that target the HER2 protein
10 Jul 2025 20:31 GMT
… ) are drugs known as PARP inhibitors. PARP proteins normally help repair … stop this from happening. PARP inhibitors work by blocking the … damaged DNA, blocking the PARP proteins often leads to the … people treated with a PARP inhibitor have developed a blood …
-
Preclinical Evaluation of a B7-H3 Targeting Antibody Enhancing NK Cell-Mediated Cytotoxicity for Ovarian Cancer Treatment
10 Jul 2025 17:18 GMT
… from maintenance therapy with PARP inhibitors. Despite these advancements … Poly-ADP-ribose polymerase (PARP) inhibitors have shown substantial … with the introduction of PARP inhibitors, as demonstrated … ; ns, not significant; PARP, Poly-ADP-ribose polymerase; …
-
PD-L1 and HRD Correlation Shows Prognostic Value in Ovarian Cancer
10 Jul 2025 20:12 GMT
… of improved PFS with the PARP inhibitor and antiangiogenic combination in … clinical trials combining immunotherapy with PARP inhibitors or antiangiogenic agents.
Additional …
-
Targeted Therapies Broaden Treatment Options for CDK4/6 Inhibitor–Resistant, HR+ Breast Cancer
10 Jul 2025 14:10 GMT
… ] question about [the efficacy of] PARP inhibition in patients with somatic …
-
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
10 Jul 2025 08:00 GMT
… instrumental in the development of PARP inhibitor, talazoparib, now commercialized by …
-
Rucaparib Benefits HRD-Negative Ovarian Cancer Subgroups
09 Jul 2025 07:55 GMT
… that the benefit of PARP inhibitor therapy in HRD- … MONO.”
Kurtz explained that PARP inhibitors may work through … cells, including immune activation.
“PARP inhibitors do something in those … benefit from maintenance therapy with PARP inhibitors, he added.
…
About
© 1995-2025